Associations Between Muscle Synergies and Treatment Outcomes in Cerebral Palsy Are Robust Across Clinical Centers.

The data were collected retrospectively as standard care, so the researchers could not plan treatment or measure outcomes prospectively. The children were not randomized to treatment, and the paper did not report how each child came to receive a particular treatment. Important clinical measures were not included, such as spasticity, metabolic cost, physical examination findings, or neurologic injury. Specific treatment details were missing, including which muscles received botulinum toxin and which surgical procedures were performed. The outcomes were limited to GDI and walking speed, which do not capture all goals of cerebral palsy treatment. Most children in the botulinum toxin group had already received botulinum toxin before the analyzed treatment, so the results may reflect repeated treatment rather than an initial course. Differences in selective dorsal rhizotomy outcomes between centers changed the model results. Some walking trials had missing or poor muscle signal channels, and the team used weighted analysis to include them.

The authors declared no conflict of interest. The publication types list research support from NIH and non-U.S. government sources.

Do not read walk-DMC as proof that a specific treatment works. The study was retrospective and only linked pre-treatment walk-DMC to later gait and speed outcomes across botulinum toxin, selective dorsal rhizotomy, single-level or multi-level orthopedic surgery, or physical therapy without botulinum toxin.